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RAZIONALE: La psoriasi è riconosciuta come uno dei più comuni disordini immuno-mediati, 
dove sia l’immunità acquisita che quella innata giocano un ruolo fondamentale nello sviluppo e 
nel mantenimento della patologia. Per tale ragione la psoriasi viene considerata un vero e 
proprio modello di studio dei meccanismi di infiammazione cronica  
Nella psoriasi si assiste alla disregolazione dell’asse citochinico IL-23/IL-17 da cui ne 
consegue da una parte l’attivazione del subset linfocitario Th-17 e dall’altra una risposta 
proliferative cheratinocitaria. 
Questo induce la secrezione di differenti citochine, chemochine e peptidi antimicrobici da parte 
dei cheratinociti stessi. L’induzione di specifici fattori chemiotattici richiama, nel sito 
dell’infiammazione, cellule dendritiche mieloidi, linfociti Th17 e neutrofili. 
Il processo infiammatorio psoriasico, oltre alle interazioni cellulari, coinvolge anche le strutture 
vascolari con il rilascio di citochine, ormoni e secondi messaggeri. È stato, inoltre, dimostrato 
che le cellule comunicano anche attraverso il rilascio di vescicole contenenti DNA, RNA, 
microRNA e proteine. Sebbene siano state riportate alterazioni del traffico micro-vescicolare in 
disturbi ematologici ed infettivi, vi sono poche evidenze di tali alterazioni nella patogenesi della 
psoriasi. 
I risultati preliminari ottenuti nei nostri laboratori indicano come l’IL-17 sia in grado di 
modificare, sia qualitativamente che quantitativamente, il carico e il rilascio extracellulare di 
vescicole. L’obiettivo del nostro studio, basato su un gruppo di ricerca multidisciplinare, è 
identificare nuovi biomarkers della psoriasi. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Background: psoriasis is a chronic inflammatory skin disease caused by the excessive 
secretion of inflammatory cytokines. Deregulation of the interleukin-23/-17 axis allows the 
activation of Th17 lymphocytes and the reprogramming of keratinocytes proliferative response, 
thereby inducing the secretion of cyto-/chemokines and antimicrobial peptides. Currently, one 
anti-IL-17 biological agent is approved for the treatment. 
Psoriasis-associated inflammation also affect systemic functions associated with 
extracutaneous manifestations. Beside cell-to-cell contacts and release of cytokines, 
hormones and second messengers, cells communicate each other through the release of 
extracellular vesicles containing DNA, RNA, microRNAs and proteins. It has been reported the 
alteration of extracellular vesicles trafficking in several diseases, but there is scarce evidence 
of the involvement of extracellular vesicles trafficking in the pathogenesis of psoriasis. 
Objective: the main goal of the study was to characterize the release, the cargo content and 
the capacity to transfer bioactive molecules of extracellular vesicles produced by keratinocytes 
following recombinant IL-17A treatment if compared to untreated keratinocytes. 
Methods: a combined approach of standard ultracentrifugation, RNA isolation and Real Time 
RT-PCR techniques was used to characterize extracellular vesicles cargo. Flow cytometry was 
used to quantitatively and qualitatively analyze extracellular vesicles and, in association with 
structured illumination microscopy, to evaluate cell-to-cell extracellular vesicles transfer. 
Results: we report that the treatment of human keratinocytes with IL-17A significantly modify 
the extracellular vesicles cargo and release. Vesicles from IL-17A-treated cells display a 
specific pattern of mRNA which is abrogated by Secukinumab neutralization. Extracellular 
vesicles are taken up by acceptor cells irrespective of their content but only those derived from 
IL-17A-treated cells enable receiving cells to express psoriasis-associated mRNA. 
Conclusion: the obtained results imply a role of extracellular vesicles in amplifying the pro-
inflammatory cascade induced in keratinocyte by pro-psoriatic cytokines. 
 
 
 
 
 
 
 
 
 
 
 
 
This work was supported by Ateneo Research Projects, Sapienza University of Rome 2016 
(C26H153BSX to CP), and 2017 (RM11715C81B4052B to GR). 
 
Introduction 
Psoriasis is an inflammatory skin disease, with chronic relapsing course. The classical clinical 
presentation consists of erythematous-scaly lesions, even if other variants have been 
described. Patients with psoriasis typically have sharply demarcated chronic erythematous 
plaques covered by silvery white scales, and the typical erythematous plaque contains 
histopathological hallmarks that include hyper-proliferation of epidermal keratinocytes and 
hyperkeratosis, as well as infiltration of immunocytes along with angiogenesis (for review see 
Mahil et al.).1 Psoriasis affects about 2% of the caucasian population and it is associated wide 
range of systemic comorbidities ranging from rheumatologic to cardiovascular disease.2, 3 
To date, the classical view of a primary keratinocytes’ dysregulation has been revised, being 
psoriasis considered as a multifactorial disease, where both innate and adaptive immunity 
have pivotal roles. Keratinocytes play as the trigger of the inflammatory response, culminating 
into the production of a pro-inflammatory cytokine network responsible for the typical dermal 
and epidermal histopathological psoriatic alterations.4 The role of Th1 and Th17 subsets in the 
pathogenesis is well characterized with a common pattern of Th1 and Th17 cytokines 
upregulation, T cell activation and local and systemic expression of endothelins and adhesion 
molecules. Surrounding the area of inflammation, activated Th1 cells produce interferon (IFN)-
γ, interleukin (IL)-2, tumor necrosis factor (TNF)-α, whereas IL-17A, IL-17F and IL-22 are 
released by Th17 cells. Binding of IL-17A with its receptor activates the transcription of nuclear 
factor-κB leading to pro-inflammatory gene expression and cytokines production, as IL-6, TNF-
α, and IL-1.5 IL-17 acts with IFN-γ by increasing the production and release of IL-6, IL-8 and 
other cytokines by keratinocytes.6 IL-8 production by keratinocytes is also induced by TNF-α, 
another pivotal cytokine in the pathogenesis of psoriasis.7 IFN-γ also stimulates the expression 
of ICAM-1 by keratinocytes, thus allowing the interaction between lymphocytes and endothelial 
cells, as well as the expression of chemokines as CXCL9, CXCL10, CXCL11 and receptors 
thereof as CXCR3.6,8 Nevertheless, some aspects in the settlement of the pro-inflammatory 
milieu remain cytokine-specific. In primary human keratinocytes IFN-α, IL-17 and IL-22 
modulate distinct and specific inflammatory response pathways.9 IL-17A treatment uniquely 
induce the expression of β-defensin 2, CXCL-1, -3, -5, -6, -8 and CCL20, thereby generating 
the influx of neutrophils, dendritic cells and memory T cells in lesional skin. Instead, IL-22 
downregulates genes involved into the differentiation of keratinocytes, thereby determining 
epidermal alterations in an organotypic skin model. Therefore, IL-17 and IL-22 mediate 
different pathways associated with clinical aspects of psoriasis: IL-17 is more proinflammatory, 
while IL-22 retards keratinocyte differentiation.9 On the other hand, the expression of Th2 
cytokines IL-4 and-13 is reduced in psoriatic lesions and they have proved to inhibit 
keratinocytes activation through STAT6, SOCS1 and SOCS3.7,10-13 Even Treg subset is 
dysregulated in psoriasis, getting the basis for chronicity.14 
Besides the release of cytokines, chemokines, growth factors and soluble messengers, cells 
communicate each other via the delivery of extracellular vesicles (EVs). Depending of their 
biogenesis and size, EVs are classified as ectosomes or Microvesicles (MVs) and exosomes.15 
All the different EVs subsets contain DNA, RNA, microRNAs and proteins able to modulate the 
functions of receiving cells. Emerging evidence demonstrates a role of EVs in a variety of 
fundamental physio- and pathological processes ranging from T cell activation to Alzheimer's 
disease also correlating their levels to poor prognosis in hematological malignancies.16-18 
Conversely, only few data correlate EVs release to inflammatory skin diseases as psoriasis. 
Seminal observations reported an increase of both endothelial- and platelet-derived circulating 
EVs in psoriatic patients.19,20 Conflicting results are obtained in anti-IL-12/23 or anti-TNF-α 
treated patients compared to untreated ones.21,22 It has been recently reported the ability of T 
cell-derived EVs to induce mast cell production of IL-24 23 as well as the ability of mast cell-
derived exosomes to present neolipid antigens to psoriatic T cells.24 No data are, instead, 
available on the ability of IL-17 to modulate the release of EVs by keratinocytes and/or their 
content in term of bioactive products. 
To test the hypothesis of an involvement of EVs in psoriasis pathogenesis, we resorted to an 
in vitro model using a spontaneously transformed keratinocyte cell line HaCaT derived from 
adult human skin. We treated these cells with recombinant human IL-17A testing, both 
quantitatively and qualitatively, the EVs release. EVs cargo was also evaluated in the 
presence of a clinical used approved neutralizing anti-IL-17A antibody (i.e. Secukinumab). 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & Methods 
Cells and Reagents. The spontaneously transformed aneuploid immortal keratinocyte HaCaT 
cell line, derived from adult human skin, was purchased from Cell Line Service GmBH 
(Eppelheim, Germany) and was cultured in Dulbecco’s Modified Essential Medium (DMEM), 
4.5 g/L glucose, supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS), 2 mM L-
glutamine, 100 UI/mL Penicillin, 100 µg/mL Streptomicin (Mediatech/Corning, Manassas, VA). 
Cells were routinely maintained in culture in a humidified atmosphere of 5.5% CO2 at 37°C. 
Recombinant human IL-17A (rIL-17A) was purchased from Peprotech (London, UK) and used 
at 100 ng/mL. 5(6)-CFDA-SE (5-(and-6)-Carboxyfluorescein Diacetate, Succinimidyl Ester, 
CFSE) was purchased from Invitrogen/Thermo Fischer Scientific (Waltham, MA). PKH67 
Green Fluorescent Cell Linker Midi Kit for General Cell Membrane Labeling and Actynomicin D 
were both purchased from Sigma-Aldrich/Merck (Saint Louis, MO). Secukinumab (Cosentyx) 
was a kind gift of Novartis Pharmaceuticals (Camberley, UK). All the experiments were 
performed using Exosome-depleted FBS Media Supplement (System Biosciences, Palo Alto, 
CA). 
EVs isolation and staining. Cells were seeded at 1.5x106 cells/mL in 100 mm diameter Petri 
dishes (Falcon/Corning, Duhram, NC). After 24 h, cells were washed in complete medium and 
stimulated for 48 hours with rIL-17A. At the end of stimulation, supernatants were collected 
and EVs isolated by serial centrifugations. Supernatants were spun 500g for 10’ and 2000g for 
10’ to remove detached cells and cellular debris, then ultracentrifugated 100,000g for 60’. 
Pellet containing EVs was either lysed to isolate total RNA or resuspended in complete 
medium or phosphate buffered saline (PBS) depending on the subsequent use. 
PHK67 fluorophore staining was performed on pelleted EVs resuspended in 0.5 µl of PHK67 in 
250 µl of Diluent C buffer, for 5’ at RT. At the end of incubation staining was stopped by adding 
250 µl of 1% Bovine Serum Albumin, 1X PBS for 1’ at RT. Exceeding dye was removed by 
ultracentrifugation. 
EVs Cytometric analysis. Cells were seeded at 1.5x106 cells/mL in a 10 cm diameter Petri 
dishes. Cells were washed twice in PBS and stained for 10’ at 37°C in serum free medium plus 
5 µM CFSE according to the manufacturer’s instruction. Cells were, then, washed twice in 
complete medium and stimulated with rIL-17A. After 48 h, supernatants were collected, EVs 
isolated as previously described and resuspended in PBS. Samples were acquired on a FACs 
ARIA II Cell Sorter equipped with FACs DiVa software v6.1.1 (Becton Dickinson, San Jose, 
CA) set with a minimal threshold (i.e. 200) on FITC channel and no thresholds on forward and 
side scatter. Acquisition field was calibrated using Megamix-Plus SSC beads (Biocytex, 
Marseille, France). Samples were acquired for 30” at minimal flow rate. To avoid carry over, 
fluidic was extensively washed with 0.1 µm filtered, distilled water before each sample 
acquisition. Results were analyzed using Flowing software v2.5.1 (Turku Centre for 
Biotechnology, University of Turku, Finland). 
EVs internalization assay and structured illumination microscopy. Cells were seeded at 
1.5x106 cells/mL in a 10 cm diameter Petri dishes and stimulated for 48 h with rIL-17A. EVs 
were collected and stained with PHK67 as described in the previous section and resuspended 
in PBS. Unstained cells were incubated at 1:1 v/v ratio with PHK67-labelled EVs at both 37°C 
and 4°C for different time then cells were analyzed by flow cytometry. For microscopic 
observations cells (2x104 per well) were seeded on 8 well Culture Slide (Corning Falcon, 
Corning, NY) in complete medium. After 24 h cells were washed with PBS, PHK67-labelled 
EVs was added and incubated for 30’ at both 4°C and 37°C. Cells were, then, washed twice 
with PBS, counterstained with 4’,6-diamino-2-phenylindole (DAPI, Sigma Aldrich, Saint Louis, 
MO) and mounted with Mowiol 4-88 Reagent (Calbiochem, Merck Millipore, Billerica, MA). 
Images were acquired on a Nikon Eclipse Ni-E microscope and processed with NIS-Elements 
AR software v4.40 (Nikon Instruments, Melville, NY). 
RNA isolation and Real Time RT-PCR on cells and EVs. Cells were seeded at 1.5x106 
cells/mL in a 10 cm diameter Petri dishes and stimulated as described in the previous section. 
Supernatants were collected and EVs were isolated as previously described, whereas cells 
were washed twice in PBS. Total RNA was extracted using the Total RNA purification Kit 
(Norgen Biotech Corp.). 500 ng of total RNA was retro-transcribed using the Tetro cDNA 
synthesis kit (Bioline) and cDNA products were analyzed by Real Time PCR using the 
SensiMix SYBR Hi-ROX Kit (Bioline). Data were normalized using as endogenous control 
HPRT-1, or 18S rRNA for EVs analysis, and expressed using the 2-ΔΔCT method.25 Primers 
used to quantify cytokines, chemokines and β-Defensin 2 were reported in Supplementary 
Table S1. 
Statistical analysis. Two-tail P value Mann-Whitney t-test was performed to compare two 
sample groups. To compare three or more groups, non-parametric ANOVA with post-hoc 
Kruskal-Wallis test was performed. *: p<0.05; **: p<0.01; ***: p<0.001. 
Ref.TableS1:(26);(27);(28);(29) 
 
 
 
 
Results 
IL-17A reduces the release of EVs. First, we tested the hypothesis that the treatment of 
keratinocytes with rIL-17A could affect both quantitatively and/or qualitatively the synthesis and 
release of MVs. For this purpose, cells were stained with CFSE, treated for 48 h with rIL-17A 
and released EVs quantified by flow cytometry. rIL-17A treatment decreased the release of 
EVs in a statistically significant manner (42.512% reduction, p<0.0001, Fig. 1a). Otherwise, 
the scatter analysis revealed a significant change in the size of EVs released by rIL-17A-
treated cells compared to untreated cultures. A reproducible increase in the percentage of 
EVs<450 nm isolated from rIL-17A treated HaCaT cells compared to untreated cells was 
observed (6.87±0.36%, Fig. 1b, 1c and Supplementary Fig. S2). Accordingly, the release of 
both EVs>800 nm and included in the range of 450 to 800 nm were reduced in IL-17A treated 
cells compared to control (2.05±1.91% and 4.81±2.21% respectively, Fig. 1b, 1c and 
Supplementary Fig. S2). As the CFSE dye does not leak out from undamaged particles, we 
also conclude that EVs were intact. 
EVs from IL-17A treated cells contain specific mRNAs. In human primary keratinocytes the 
treatment with IL-17A induces a specific molecular signature characterized by the upregulation 
of 28 genes.9 Between these, the most expressed are b-Defensin 2 and the neutrophil 
chemoattractants CXCL1, -3, -5, -6 and -8. IL-17A also induces the expression of CCL20 
which regulate memory T and dendritic cells traffic. We, then, tested the presence of these 
mRNAs in EVs isolated from rIL-17A-treated cells. HaCaT cells were treated from 1 to 72 
hours with rIL-17A and the expression of several pro-inflammatory cytokines and chemokines 
mRNA was tested by RT Real Time PCR. In our experimental system all the chemokines 
previously reported as upregulated by IL-17A were induced at different degrees and with 
different kinetics (Supplementary Fig. S3). We also detected the upregulation of IL-6 mRNA 
as already observed in IL-17 treated murine keratinocyte.30 All these effects were IL-17A-
dependent because Secukinumab pre-treatment abrogate these inductions. Then, we 
analyzed the mRNA content in EVs isolated from both untreated keratinocytes or treated for 72 
hours with rIL-17A. EVs isolated from rIL-17A treated cells, embedded mRNA for all 
chemokines and b-Defensin 2 but not IL-6 and CXCL-8. Again, this feature was completely 
abrogated by Secukinumab pre-treatment (Fig. 2). 
Chronic exposure to IL-17A induces higher b-Defensin 2 mRNA expression in EVs. In 
vivo psoriatic keratinocytes were continuously exposed to IL-17A produced by chronically 
activated Th17 lymphocytes.31 We simulated chronic exposure by stimulating HaCaT cells for 
5 days with IL-17A either in acute mode (i.e. one stimulation at the beginning of the 
experiment) or in chronic stimulation (i.e. daily stimulation with the cytokine), to test if there are 
any differences between these conditions. Between the previously tested 
cytokines/chemokines, we measured higher levels of β-Defensin 2 mRNA in samples exposed 
to IL-17A in chronic rather than in acute manner in both cells and EVs (Fig. 3a and 3b, 
respectively). According to the kinetic of induction in cells, a shorter (i.e. 72 hours) chronic rIL-
17A treatment up-regulated the expression of mRNAs of CCL20 and CXCL3 to a greater 
extent than an acute stimulation in EVs (data not shown). These results suggest that chronic 
exposure to IL-17A quantitatively improves the cargo content of EVs. 
EVs are internalized by acceptor cells irrespectively of IL-17A. Once we recorded the 
ability of HaCaT cells to release EVs, we tested the hypothesis that these vesicles could be 
transferred to acceptor cells. Then, we isolated EVs from untreated (Ctr-EVs) or IL-17A-treated 
(IL-17A-EVs) HaCaT cells, staining them with PHK67, a green fluorescent dye able to label 
membranes. In both cases, acceptor unstained HaCaT cells were incubated for different time 
points with stained EVs. Incubation was performed at both 37°C or 4°C to discriminate 
between EVs endocytosis and surface adsorption, respectively. EVs were rapidly internalized 
by acceptor cells as 30 to 40 % of acceptor cells were positive to PHK67 when incubated at 
37°C for 5’ but not at 4°C, thereby excluding any adsorption to acceptor cell surface (Fig. 4a). 
Internalization curves of HaCaT treated with Ctr-EVs and IL-17A-EVs were superimposable. 
Nevertheless, Mean Fluorescence Intensity (MFI) of acceptor cells treated with IL-17A-EVs are 
slightly higher than Ctr-EVs (Fig. 4b). We also perform immunofluorescence analysis on EVs 
treated cells using structured illumination microscopy. Again, both Ctr-EVs (Fig. 4c) and IL-
17A-EVs (Fig. 4d) were internalized at 37°C with the same efficiency and no major differences 
in the intracellular localization was detected whereas no fluorescence was detected at 4°C 
(data not shown). 
b-Defensin 2 mRNA is over-represented in acceptor cells. In view of the previously 
reported results, we wondered if cargo mRNAs could be transferred to acceptor cells. 
Therefore, HaCaT cells were treated with both Ctr-EVs and IL-17A-EVs. Acceptor cells were 
daily stimulated with EVs for 5 days to simulate chronic exposure to EVs (Fig. 5a) and, to 
monitor the cargo transfer, we measured the b-Defensin 2 mRNA as readout. As depicted in 
Fig. 5b b-Defensin 2 mRNA was specifically upregulated in cells treated with IL-17A-EVs. 
IL-17A-EVs specifically induces endogenous b-Defensin 2 mRNA in acceptor 
keratinocytes. Based on the previous result, two possible scenarios are conceivable: i) IL-
17A-EVs transfer their cargo to acceptor cells enabling them to express “exogenous” mRNAs 
or ii) IL-17A-EVs allow acceptor cells to express endogenous b-Defensin 2 mRNA. To 
discriminate between these two hypotheses, acceptor cells were pre-treated with Actinomycin 
D thereby interfering with cellular mRNA synthesis, then incubated with EVs collected from 
both donor untreated or IL-17A-treated cells, containing b-Defensin 2 mRNA (Fig. 6a). Cells 
pre-treated with Actinomycin D failed to upregulate b-Defensin 2 mRNA following IL-17A-EVs 
challenge (Fig. 6b). As Actinomycin D was unable to inhibit the expression in acceptor cells of 
a viral derived mRNA (i.e. HPV-16 E6 mRNA shipped by CaSki-derived EVs, Supplementary 
Fig. S3), these results suggest that EVs derived from IL-17A treated keratinocytes, but not 
from untreated cells, are able to induce the expression of specific mRNAs (i.e. b-Defensin 2) in 
acceptor cells in the absence of the primitive stimulus (i.e. IL-17A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
The increased knowledge of EVs biology and their ability to enrich tissue-specific biomarkers 
in normal and pathological conditions, suggest that they may provide a valuable tool to identify 
diagnostic signatures, develop new diagnostic assays and help guide therapeutic approaches. 
In the case of psoriasis, the comprehension of the role of EVs relased from different cell type 
(i.e. Th17 cells, mieloid dendritic cells, keratinocytes, mast cells) is just at an early stage. 
Reports have demonstrated an increase in the number of circulating EVs derived form 
platelets and endotelial cells in patients compared to healthy subjects19,20 but none addressed 
the issue of keratinocytes-derived EVs. Our in vitro model suggests that IL-17A, a driver 
cytokine in the pathogenesis of psoriasis, reduces the delivery of EVs (Fig. 1a). Differences 
between our data and those reported by others are due by either the different system used 
(i.e. plasma form patients versus cell culture supernantants) and by the different nature of 
producing cells (i.e. platelet/endothelial cells versus keratinocytes). We also observed an effect 
of IL-17A in the size of the EVs population released by keratinocytes. Indeed, EVs produced 
from IL-17A-treated cells are smaller in size compared to those released from untreated cells 
(Fig. 1b) suggesting the presence in the former sample of a heterogeneous population of EVs 
mostly composed from exosomes and/or small MVs (in the range of 100 nm). The exposure of 
HaCaT cells to IL-17A not only have a sizeable impact on the EVs release, but also affect their 
cargo in terms of mRNA. Results obtained in EVs isolated from IL-17A-treated HaCaT cells 
(Fig. 2) demonstrate the presence of mRNAs for chemokines/alarmins representing an IL-17A-
specific signature overlapping the intracellular expression pattern in keratinocytes.9 According 
to Nograles et al., the most induced mRNA in both cells and EVs is b-Defensin 2 also in our 
experimental system. b-Defensin 2 is a psoriasis-associated marker together with CCL20, 
another mRNA we founded up-regulated in IL-17A-EVs.32,33 Another streaking feature is the 
ability of Secukinumab to inhibit the expression of IL-17A-related mRNAs in EVs and in 
keratinocytes. Nevertheless, Secukinumab does not reduce the release of EVs (Data not 
shown). This suggest that EVs release takes place through an IL-17A-independent pathway, 
whereas EVs cargo is Secukinumab-sensitive. 
Beside the prognostic/diagnostic use, EVs represent an almost unexplored way of cell-to-cell 
and cell-to-extracellular matrix communication. From this point of view one of the crtitcal step 
is the interaction between EVs and target/acceptor cells. Our results (Fig. 4) demonstrate that 
not only EVs derived by keratinocytes homotypically interact with acceptor cells but also that 
these EVs are internalized. Fluorescent-labelled EVs stain at 37°C, but not at 4°C, acceptor 
HaCaT cells regardless of rIL-17A treatment of donor cells. This suggest that the interaction 
between EVs and acceptor cells arise trough a molecule constitutively expressed on EVs 
surface. Nevertheless, only EVs derived from cells treated with IL-17A induce the expression 
of b-Defensin 2 mRNA in acceptor cells. Results obtained pre-treating acceptor cells with 
Actinomycin D indicate that the b-Defensin 2 mRNA expression is due to de novo synthesis of 
endogenous mRNA rather than the transfer from donor to acceptor cells. Indeed, when EVs 
expressing a heterologous viral mRNA (i.e. HPV-16 E6 mRNA) were used, Actinomycin D is 
unable to inhibit its expression in acceptor cells (Supplementary Fig. S3). Since it is known 
that, Depending on concentration, Actinomycin D blocks pinocytosis and endocytosis,34,35 
using fluorescent-labelled EVs we verified that the concentration used was able to inhibit RNA 
neo-synthesis but not pino- and endocytosis (data not shown). 
Our results indicate that IL-17A affects the production of EVs and their size in keratinocytes 
also reshaping the cargo content through the overexpression of psoriasis-associated mRNAs 
like b-Defensin 2. These EVs interact and are internalized by acceptor cells which, in turn, 
express b-Defensin 2 in the absence of primitive stimulus (i.e. IL-17A). This mechanism could 
play a role in the amplification of the chronic inflammatory state in the surroundings of the 
psoriatic lesions and, if EVs reach the blood stream, a role in the dissemination of the disease 
in other anatomical sites as heart, eye or joints in the case of psoriatic arthritis could be also 
hypothesized. 
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Figure Legends 
 
 
Figure 1. IL-17A reduces the release of EVs. Cells (5x105) were seeded in 60 mm diameter 
Petri dishes. After 24 h, cells were stained with CFSE and stimulated for 72 h with rIL-17A 
(100 ng/mL). Supernatants were collected, EVs isolated and acquired on a FACs ARIA II 
cytometer. (a) CFSE positive EVs were enumerated, normalized to cell counts and results are 
expressed as percentage compared to untreated cells. Blue bar: EVs from untreated cells 
(Ctr); red bar: EVs from IL-17A treated cells. (b) A representative dot plot of CFSE stained EVs 
derived from untreated (left panel) and rIL-17A treated cells (100 ng/mL, right panel). EVs 
sizes were set according to the calibration beads size. (c) The variation in the EVs sub-
populations in response to rIL-17A treatment was expressed as the difference between the 
percentage of each EVs sub-population measured in IL-17A treated cells and the percentage 
in untreated controls (Δ%). 
 
 
 
 
 
 
 
 
 
 
  
Figure 2. EVs from IL-17A treated cells contain specific mRNAs. Cells (1.5x106 in 100 mm 
diameter Petri dishes) were stimulated for 72 h with rIL-17A (100 ng/mL) pre-incubated for 1 h 
at 37°C with or without Secukinumab, with Secukinumab alone or left untreated. Supernatants 
were collected, EVs were isolated, total RNA was purified and Real Time RT-PCR was 
performed as described in materials and methods section. Results were expressed as fold of 
induction (n-Fold) according to the 2-ΔΔCT method, using the value of control as reference and 
the value of RNA 18S as an internal loading control. Blue bar: EVs from untreated cells (Ctr); 
red bar: EVs from rIL-17A treated cells; light blue bar: EVs from Secukinumab (Secuk) treated 
cells; light red bar: EVs from Secukinumab plus IL-17A treated cells. 
 
 Figure 3. Chronic exposure to IL-17A induces higher b-Defensin 2 mRNA expression in 
EVs. Cells (1.5x106 in 100 mm diameter Petri dishes) were stimulated for 72 h with rIL-17A 
(100 ng/mL) or left untreated. Supernatants were collected and EVs were isolated whereas 
cells were washed twice in PBS and lysed. Total RNA was purified, and β-Defensin 2 Real 
Time RT-PCR was performed on both cells (a) or EVs (b) as described in materials and 
methods section. Results were expressed as fold of induction (n-Fold) according to the 2-ΔΔCT 
method, using the value of control as reference and the value of RNA 18S (EVs) and HPRT-1 
(Cells) as internal loading controls. Ctr: untreated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4. EVs is internalized by acceptor cells irrespectively of IL-17A. (a, b) Cells were 
seeded at 1.5x106 in 100 mm diameter Petri dishes. After 24 h, cells were stimulated for 72 h 
with rIL-17A (100 ng/mL). At the end of the stimulation, supernatants were collected and EVs 
were isolated and stained with PHK67 as described in materials and methods. HaCat cells 
(105 cells/100 µl in PBS) were incubated with PHK67-labeled EVs in a 1:1 v/v ratio for 5’, 15’, 
30’, 45’ and 60’ at both 37°C or 4°C. Incubation was stopped by adding 900 µl of cold PBS and 
cells were analyzed by flow cytometry. Results were expressed as percentage of PHK67 
positive cells (a) or as Mean Fluorescent Intensity (MFI, b). Blue line: untreated cells, 37°C; 
red line: rIL-17A, 37°C; light blue line: untreated cells, 4°C; light red line: rIL-17A, 4°C. (c, d) 
Cells (5x105) were seeded in 60 mm diameter Petri dishes. After 24 h, cells were stimulated 
for 72 h with rIL-17A (100 ng/mL). At the end of the stimulation, supernatants were collected 
and EVs were isolated and stained with PHK67 as described in materials and methods. HaCat 
cells (2x104 cells) were seeded on culture slide and incubated for 30’ at 37°C with PHK67-
labeled EVs. (c) HaCaT cells treated with EVs from unstimulated cells; (d) HaCaT cells treated 
with EVs from rIL-17A stimulated cells. 
 
 
 
  
Figure 5. b-Defensin 2 mRNA is overrepresented in acceptor cells. Donor cells (1.5x106 in 
100 mm diameter Petri dishes) were daily stimulated for 5 days with rIL-17A (100 ng/mL) or 
left untreated. Supernatants were collected, EVs from rIL-17A-treated cells (IL-17A-EVs) and 
from unstimulated cells (Ctr-EVs) were isolated and then added to acceptor cells seeded at 
1.5x106 in 100 mm diameter Petri dish. Acceptor cells were incubated with or without EVs for 
24 h then washed twice in PBS and lysed. Total RNA was purified, and β-Defensin 2 Real 
Time RT-PCR was performed as described in materials and methods section on both donor 
(a) and acceptor cells (b). Results were expressed as fold of induction (n-Fold) according to 
the 2-ΔΔCT method, using the value of control as reference and the value of HPRT-1 as an 
internal loading control. Ctr: untreated cells.  
 
 
 Figure 6. IL-17A-EVs specifically induce endogenous b-Defensin 2 mRNA in acceptor 
keratinocytes. Donor cells (1.5x106 in 100 mm diameter Petri dishes) were daily stimulated 
for 5 days with rIL-17A (100 ng/mL) or left untreated. Supernatants were collected, EVs from 
rIL-17A-treated cells (IL-17A-EVs) and from unstimulated cells (Ctr-EVs) were isolated. 
Acceptor cells were seeded at 1.5x106 in 100 mm diameter Petri dish and pre-treated with 
Actinomycin D (500 ng/mL) for 30’ at 37°C or left untreated. Cells were, then, washed twice 
with medium and stimulated with or without EVs for 24 h at 37°C. At the end of the stimulation 
cells were washed twice in PBS and lysed. Total RNA was purified, and β-Defensin 2 Real 
Time RT-PCR was performed as described in materials and methods section on both donor 
(a) and acceptor cells (b). Results were expressed as fold of induction (n-Fold) according to 
the 2-ΔΔCT method, using the value of control as reference and the value of HPRT-1 as an 
internal loading control. Ctr: untreated cells; Act D: Actinomycin D. 
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Supplementary Figure S2. IL-17A alters the relative expression of EVs sub-populations. 
Cells (5x105) were seeded in 60 mm diameter Petri dishes. After 24 h, cells were stained with 
CFSE and stimulated for 72 h with rIL-17A (100 ng/mL). Supernatants were collected, EVs 
isolated and acquired on a FACs ARIA II cytometer as described in materials and methods. 
CFSE positive EVs were enumerated and the results were expressed as the percentage of 
positive cells belonging to each subpopulation. Blue bar: EVs from untreated cells (Ctr); red 
bar: EVs from IL-17A treated cells.  
 
 
 
 Supplementary Figure S3. Cells treated with IL-17A contain specific mRNAs. Cells 
(1.5x106 in 100 mm diameter Petri dishes) were stimulated for 1, 6, 24, 48 and 72 h with rIL-
17A (100 ng/mL) pre-incubated for 1 h at 37°C with or without Secukinumab, with 
Secukinumab alone or left untreated. Cells were washes twice with PBS and lysed. Total RNA 
was purified, and Real Time RT-PCR was performed as described in materials and methods 
section. Results were expressed as fold of induction (n-Fold) according to the 2-ΔΔCT method, 
using the value of control as reference and the value of RNA 18S as an internal loading 
control. Blue line: untreated cells (Ctr); red line: rIL-17A; light blue line: Secukinumab (Secuk); 
light red line: Secukinumab plus rIL-17A. 
 
 
 
 Supplementary Figure S4. Actinomycin D is unable to inhibit HPV16 E6 mRNA 
expression in acceptor keratinocytes. CaSki cells (1.5x106 in 100 mm diameter Petri 
dishes) were cultured for 5 days at 37°C. Supernatants were collected and EVs were isolated. 
Acceptor HaCaT cells were seeded at 1.5x106 in 100 mm diameter Petri dish and pre-treated 
with Actinomycin D (500 ng/mL) for 30’ at 37°C or left untreated. Cells were, then, washed 
twice with medium and stimulated with or without EVs for 24 h at 37°C. At the end of the 
stimulation cells were washed twice in PBS and lysed. Total RNA was purified, and HPV16 E6 
Real Time RT-PCR was performed as described in materials and methods section on acceptor 
cells. Results were expressed as fold of induction (n-Fold) according to the 2-ΔΔCT method, 
using the value of control as reference and the value of HPRT-1 as an internal loading control. 
Ctr: untreated cells; Act D: Actinomycin D. 
 
